Heteroaromatic Enzyme Interacting Agents for Sphingolipid Pathways
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current studies on sphingolipid enzymes, such as sphingosine kinase 1 (SphK1) and dihydroceramide desaturase-1 (Des1), face a lack of suitable exogenous agents that can effectively interact with these enzymes, hindering research and therapeutic applications in diseases like cancer, fibrosis, and inflammation.
Innovation Solution
Development of non-sphingolipid-like heteroaromatic compounds that interact with specific binding sites of SphK1, SphK2, and Des1, offering potential as research tools and therapeutic agents to modulate enzyme activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current studies use existing agents to interact with sphingolipid enzymes, then research can be conducted, but the agents lack effectiveness and suitability for targeting SphK1, SphK2, and Des1
Solution Approach 1:
The patent applies parameter changes by modifying molecular structure parameters to create compounds with optimized interactions. The compounds of Formula (I) feature specific heteroaromatic ring systems (Q) with defined substitution patterns (Ra, Rb, Rc, Rd) and linker groups (L), creating a series of structurally related compounds with varying binding affinities. This systematic variation of molecular parameters enables identification of compounds with high effectiveness and specificity for SphK1, SphK2, and Des1 enzymes.
Solution Approach 2:
The patent applies local quality by designing compounds with specific functional groups positioned at particular locations within the molecular structure. The heteroaromatic ring Q contains heteroatoms (N, O, S) at specific positions, and substituents (Ra, Rb, Rc, Rd) are placed at defined locations to create localized interaction zones. This local optimization of chemical properties at specific molecular regions enhances the compounds' ability to selectively interact with target enzymes.
2Productivity
If no suitable exogenous agents are available, then research progress is hindered, but developing new compounds requires significant time and resources
Solution Approach 1:
The patent applies preliminary action by pre-designing and synthesizing a series of compounds with predicted favorable properties before conducting biological screening. The compounds of Formula (I) are designed in advance with specific structural features known to interact with sphingolipid enzymes, and their structures are optimized beforehand based on molecular modeling and structure-activity relationship analysis. This preliminary preparation accelerates the research process by having ready-to-test compounds with high probability of activity.
Solution Approach 2:
The patent applies universality by creating a compound series that can potentially interact with multiple sphingolipid enzymes (SphK1, SphK2, and Des1) through shared structural features. The core heteroaromatic structure with variable substituents provides a universal scaffold that maintains fundamental enzyme-interaction capabilities while allowing optimization for specific targets. This multi-functional design enables a single compound series to serve multiple research purposes.
3Measurement precision
If compounds are designed to selectively interact with specific binding sites, then specificity is improved, but the complexity of molecular design increases
Solution Approach 1:
The patent applies segmentation by dividing the molecular structure into distinct functional segments: the core heteroaromatic ring Q, the linker group L, and the substituent groups (Ra, Rb, Rc, Rd). Each segment serves a specific function in enzyme interaction, allowing independent optimization and analysis. This segmented design simplifies the complex task of achieving specificity by enabling systematic modification of individual segments to tune binding properties.
Solution Approach 2:
The patent applies the intermediary principle by using the linker group L as a mediator between the heteroaromatic ring Q and the substituent groups (Ra, Rb, Rc, Rd). The linker (selected from —NH—, —*NH—CH2—, —*CH2—NH—, *NH—NH—, and —*C(═O)—NH—) acts as a flexible connector that allows the different parts of the molecule to adopt optimal orientations for enzyme binding while maintaining overall structural integrity. This intermediary element simplifies the design of complex three-dimensional binding geometries.
Data Source
AI summary
The present disclosure relates generally, but not exclusively, to compounds and their use as enzyme interacting agents, in particular, agents which interact with one or more enzymes in the sphingolipid biosynthesis pathway. The disclosure further relates to the use of such compounds as research tools, use in therapy, to compositions and agents comprising said compounds, and to methods of treatment using said compounds.